Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023
Data on reinfection in large Asian populations are limited. In this study, we aimed to evaluate the reinfection rate, disease severity, and time interval between the infections in the symptomatic and asymptomatic populations which are firstl infected with BA.2 Omicron Variant. We retrospectively inc...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2023.2292071 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850169967031353344 |
|---|---|
| author | Jianpeng Cai Haocheng Zhang Kun Zhu Feng Zhu Yan Wang Sen Wang Faren Xie Meng Zhang Lili Rui Shuhong Li Ke Lin Quanlin Xue Guanmin Yuan Hongyu Wang Yi Zhang Zhangfan Fu Jieyu Song Yanliang Zhang Jingwen Ai Wenhong Zhang |
| author_facet | Jianpeng Cai Haocheng Zhang Kun Zhu Feng Zhu Yan Wang Sen Wang Faren Xie Meng Zhang Lili Rui Shuhong Li Ke Lin Quanlin Xue Guanmin Yuan Hongyu Wang Yi Zhang Zhangfan Fu Jieyu Song Yanliang Zhang Jingwen Ai Wenhong Zhang |
| author_sort | Jianpeng Cai |
| collection | DOAJ |
| description | Data on reinfection in large Asian populations are limited. In this study, we aimed to evaluate the reinfection rate, disease severity, and time interval between the infections in the symptomatic and asymptomatic populations which are firstl infected with BA.2 Omicron Variant. We retrospectively included adult patients with COVID-19 discharged from four designated hospitals between 27 April 2021 and 30 November 2022, who were interviewed via telephone from 29 January to 1 March 2023. Univariable and multivariable analyses were used to explore risk factors associated with reinfection. A total of 16,558 patients were followed up, during the telephone survey of an average of 310.0 days, 1610 (9.72%) participants self-reported reinfection. The mean time range of reinfection was 257.9 days. The risks for reinfection were analysed using multivariable logistic regression. Patients with severe first infection were at higher risk for reinfection (aORs, 2.50; P < 0.001). The male (aORs,0.82; P < 0.001), the elderly (aORs, 0.44; P < 0.001), and patients with full vaccination (aORs, 0.67; P < 0.001) or booster (aORs, 0.63; P < 0.001) had the lower risk of reinfection. Patients over 60 years of age (aORs,9.02; P = 0.006) and those with ≥2 comorbidities (aORs,11.51; P = 0.016). were at higher risk for severe reinfection. The number of clinical manifestations of reinfection increases in people with severe first infection (aORs, 2.82; P = 0.023). The overall reinfection rate was 9.72%, and the reinfection rate of Omicron-to-Omicron subvariants was 9.50% at one year. The severity of Omicron-Omicron reinfection decreased. Data from our clinical study may provide clinical evidence and bolster response preparedness for future COVID-19 reinfection waves. |
| format | Article |
| id | doaj-art-54db2e2b9fdd4bd095165d6161c2b25e |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-54db2e2b9fdd4bd095165d6161c2b25e2025-08-20T02:20:37ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512024-12-0113110.1080/22221751.2023.2292071Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023Jianpeng Cai0Haocheng Zhang1Kun Zhu2Feng Zhu3Yan Wang4Sen Wang5Faren Xie6Meng Zhang7Lili Rui8Shuhong Li9Ke Lin10Quanlin Xue11Guanmin Yuan12Hongyu Wang13Yi Zhang14Zhangfan Fu15Jieyu Song16Yanliang Zhang17Jingwen Ai18Wenhong Zhang19Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Respiratory and Critical Care Medicine, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi Fifth People's Hospital, Wuxi, People’s Republic of ChinaDepartment of Infectious Diseases, The Sixth People’s Hospital of Shenyang, Shenyang, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaData on reinfection in large Asian populations are limited. In this study, we aimed to evaluate the reinfection rate, disease severity, and time interval between the infections in the symptomatic and asymptomatic populations which are firstl infected with BA.2 Omicron Variant. We retrospectively included adult patients with COVID-19 discharged from four designated hospitals between 27 April 2021 and 30 November 2022, who were interviewed via telephone from 29 January to 1 March 2023. Univariable and multivariable analyses were used to explore risk factors associated with reinfection. A total of 16,558 patients were followed up, during the telephone survey of an average of 310.0 days, 1610 (9.72%) participants self-reported reinfection. The mean time range of reinfection was 257.9 days. The risks for reinfection were analysed using multivariable logistic regression. Patients with severe first infection were at higher risk for reinfection (aORs, 2.50; P < 0.001). The male (aORs,0.82; P < 0.001), the elderly (aORs, 0.44; P < 0.001), and patients with full vaccination (aORs, 0.67; P < 0.001) or booster (aORs, 0.63; P < 0.001) had the lower risk of reinfection. Patients over 60 years of age (aORs,9.02; P = 0.006) and those with ≥2 comorbidities (aORs,11.51; P = 0.016). were at higher risk for severe reinfection. The number of clinical manifestations of reinfection increases in people with severe first infection (aORs, 2.82; P = 0.023). The overall reinfection rate was 9.72%, and the reinfection rate of Omicron-to-Omicron subvariants was 9.50% at one year. The severity of Omicron-Omicron reinfection decreased. Data from our clinical study may provide clinical evidence and bolster response preparedness for future COVID-19 reinfection waves.https://www.tandfonline.com/doi/10.1080/22221751.2023.2292071SARS-CoV-2COVID-19Omicron variantreinfectionfollow-up study |
| spellingShingle | Jianpeng Cai Haocheng Zhang Kun Zhu Feng Zhu Yan Wang Sen Wang Faren Xie Meng Zhang Lili Rui Shuhong Li Ke Lin Quanlin Xue Guanmin Yuan Hongyu Wang Yi Zhang Zhangfan Fu Jieyu Song Yanliang Zhang Jingwen Ai Wenhong Zhang Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023 Emerging Microbes and Infections SARS-CoV-2 COVID-19 Omicron variant reinfection follow-up study |
| title | Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023 |
| title_full | Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023 |
| title_fullStr | Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023 |
| title_full_unstemmed | Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023 |
| title_short | Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023 |
| title_sort | risk of reinfection and severity with the predominant ba 5 omicron subvariant china from december 2022 to january 2023 |
| topic | SARS-CoV-2 COVID-19 Omicron variant reinfection follow-up study |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2023.2292071 |
| work_keys_str_mv | AT jianpengcai riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT haochengzhang riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT kunzhu riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT fengzhu riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT yanwang riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT senwang riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT farenxie riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT mengzhang riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT lilirui riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT shuhongli riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT kelin riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT quanlinxue riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT guanminyuan riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT hongyuwang riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT yizhang riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT zhangfanfu riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT jieyusong riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT yanliangzhang riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT jingwenai riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 AT wenhongzhang riskofreinfectionandseveritywiththepredominantba5omicronsubvariantchinafromdecember2022tojanuary2023 |